- Lilly Acquires Calytrix Bio in $1.5B Deal Amid $32B Buying Spree
Eli Lilly has agreed to acquire closely held Calytrix Bio in a deal that could be worth up to $1.5 billion. This acquisition is part of Lilly's ongoing strategy to enhance its cancer and immunology businesses, contributing to a total of over $32 billion in acquisitions throughout 2026.
Deals·1 article / 1 outlet·2d ago
- Danes Are Crooning Over Novo Despite Drugmaker’s Share Slump
It’s been a painful couple of years for Denmark’s nearly 700,000-strong army of retail investors in Novo Nordisk A/S as the weight-loss drugmaker has lost market share to US rival Eli Lilly & Co.
Macro·1 article / 1 outlet·4d ago
- Lilly Expands Acquisition Strategy with $1.5B Calytrix Purchase
Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses.
Deals·2 articles / 2 outlets·5d ago
- Lilly’s Obesity Drug Zepbound Helped Adolescents Lose Weight
Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped children aged 12 and older safely lose weight in a new study. This development bolsters the drugmaker’s efforts to break into the market for younger patients.
Product·1 article / 1 outlet·5d ago
- FDA Requires Warning Label on Weight-Loss Drugs for Vision Risk
Novo Nordisk A/S and Eli Lilly & Co. must warn weight-loss drug users of a possible rare side effect that could affect their vision, following a new requirement from the Food and Drug Administration.
Product·1 article / 1 outlet·12d ago
- Eli Lilly's Foundayo Pill Helps Control Sleep Apnea in Two Large Trials
Eli Lilly & Co.’s weight loss pill Foundayo helped control sleep apnea in two large trials, reducing nighttime disruptions for patients and paving the way for a new use for the daily drug.
Product·2 articles / 2 outlets·12d ago
- Lilly Partners With Hims & Hers to Expand Obesity Drug Access↩
Eli Lilly & Co. will now team up with Hims & Hers Health Inc. to make its blockbuster obesity medicines more widely available, tapping into the telehealth company’s vast customer base to boost sales of drugs including its new weight-loss pill Foundayo.
Deals·1 article / 1 outlet·15d ago
- Dublin's Reliance on Corporations: 50% of Taxes from Apple, Eli Lilly, and Microsoft
Dublin's economy is heavily dependent on corporation taxes, with half of these revenues coming from just three companies: Apple, Eli Lilly, and Microsoft.
Macro·1 article / 1 outlet·19d ago
- Eli Lilly Raises Sales Outlook on Strong Demand for Zepbound and Mounjaro
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Guidance·2 articles / 2 outlets·22d ago
- Eli Lilly Raises Price Target Amid Continued Obesity Drug Growth
Eli Lilly is experiencing significant growth driven by its obesity drugs Mounjaro and Zepbound. The company is optimistic about further expansion in this market.
Guidance·1 article / 1 outlet·23d ago
- Eli Lilly Raises Forecast, EBay Jumps on Results
Eli Lilly (LLY) is climbing in early trading after the drugmaker boosted its revenue guidance for the full year, following better-than-expected sales in the third quarter.
Guidance·1 article / 1 outlet·23d ago
- Eli Lilly Reports Q3 Earnings Driven By Zepbound And Mounjaro
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
Earnings·1 article / 1 outlet·23d ago